BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7262161)

  • 1. A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.
    Cavalli F; Klepp O; Renard J; Röhrt M; Alberto P
    Eur J Cancer (1965); 1981 Feb; 17(2):245-9. PubMed ID: 7262161
    [No Abstract]   [Full Text] [Related]  

  • 2. VP16-213 as a single agent in advanced testicular tumors.
    Fitzharris BM; Kaye SB; Saverymuttu S; Newlands ES; Barrett A; Peckham MJ; McElwain TJ
    Eur J Cancer (1965); 1980 Sep; 16(9):1193-7. PubMed ID: 7227446
    [No Abstract]   [Full Text] [Related]  

  • 3. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
    Suzuki K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VP-16-213 (etoposide) in the management of germinal testis tumors.
    Pizzocaro G
    Prog Clin Biol Res; 1985; 203():391-400. PubMed ID: 2421333
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of etoposide in testicular tumors].
    Tanahashi T; Matsumura Y; Ozaki Y; Yoshimoto J; Tsushima T; Obama T; Akagi T; Nasu Y; Ohmori H
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):3074-7. PubMed ID: 3767390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide: a new anti-cancer agent.
    Arnold AM; Whitehouse JM
    Lancet; 1981 Oct; 2(8252):912-5. PubMed ID: 6117692
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

  • 8. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
    Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [VM-26 and VP-16 salvage therapy for refractory germinal testicular cancers].
    Miki T; Tomooka Y; Yoshimura K; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
    Nihon Hinyokika Gakkai Zasshi; 1989 Nov; 80(11):1609-16. PubMed ID: 2593435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
    Panduro J; Hansen M; Hansen HH
    Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
    [No Abstract]   [Full Text] [Related]  

  • 11. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
    Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN
    Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617
    [No Abstract]   [Full Text] [Related]  

  • 12. [Complete remission obtained in advanced testicular cancer treated by etoposide (NK-171)].
    Babaya K; Tsumatani K; Natsume O; Yoshie T; Kubota K; Ozono S; Hirao Y; Okajima E
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):604-7. PubMed ID: 2420282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 14. Etoposide (VP 16-213; VePesid).
    Med Lett Drugs Ther; 1984 May; 26(661):48-9. PubMed ID: 6325855
    [No Abstract]   [Full Text] [Related]  

  • 15. Etoposide (VP-16-213). Current status of an active anticancer drug.
    O'Dwyer PJ; Leyland-Jones B; Alonso MT; Marsoni S; Wittes RE
    N Engl J Med; 1985 Mar; 312(11):692-700. PubMed ID: 2983208
    [No Abstract]   [Full Text] [Related]  

  • 16. Etoposide for therapy-resistant testicular tumors.
    Varini M; Cavalli F
    Cancer Treat Rev; 1982 Jun; 9 Suppl():73-8. PubMed ID: 7127337
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
    Vaughn CB; Panettiere F; Thigpen T; Bottomley R; Hoogstraten B; Samal B
    Cancer Treat Rep; 1981; 65(5-6):443-5. PubMed ID: 7237465
    [No Abstract]   [Full Text] [Related]  

  • 18. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
    Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
    Grunberg SM; Felman IE; Gala KV; Johnson KB; Owens JC
    Am J Clin Oncol; 1985 Oct; 8(5):393-5. PubMed ID: 4061373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
    Crivellari D; Veronesi A; Magri MD; Tirelli U; Comoretto R; Barzan L; Caruso G; Carbone A; Grigoletto E
    Tumori; 1985 Oct; 71(5):499-500. PubMed ID: 4060251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.